SEBI Reg. Investment Advisor

Download App

MoneyWorks4Me

Cipla’s arm inks definitive agreement to sell its entire 48.22% stake in Jiangsu

10 Dec 2014 Evaluate

Cipla’s wholly owned subsidiary - Meditab Holdings, Mauritius, has entered into a definitive agreement to sell its entire 48.22% equity interest in Jiangsu Cdymax Pharmaceuticals Company, China (Jiangsu) to an affiliate of one of the other shareholders of Jiangsu, for a total consideration of $18.5 million. The closing of the transaction is subject to receipt of applicable regulatory approvals in China.

Cipla has emerged as one of the most respected pharmaceutical names in India as well as across more than 170 countries. Its portfolio includes 2000 products in 65 therapeutic categories with one quality standard globally.

Cipla Share Price

1233.60 -4.70 (-0.38%)
20-Apr-2026 09:59 View Price Chart
Peers
Company Name CMP
Sun Pharma Inds. 1673.75
Dr. Reddys Lab 1235.00
Cipla 1233.60
Zydus Lifesciences 937.25
Lupin 2328.00
View more..

About MoneyWorks4Me

MoneyWorks4Me is a SEBI-registered Investment Adviser (IA) dedicated to helping investors build long-term wealth through transparent, research-driven, conflict-free guidance. Founded in 2008, we started our journey as a Research Analyst (RA), providing deep fundamental analysis, intrinsic value insights, and long-term investing frameworks for Indian equities. In 2017, we transitioned to a full-fledged SEBI-registered Investment Adviser, strengthening our commitment to acting as a fiduciary—always putting the investor’s interest first.

Our Vision

To become India’s most trusted, research-powered fiduciary advisory platform—where every investor, regardless of experience, can make calm, confident, and well-reasoned investment decisions.

What Makes MoneyWorks4Me Different

Our Approach: Ensuring compounding work its magic on client portfolio.

MoneyWorks4Me ensures this through:

×